Sickle Cell Disease and the Case for Genomic Screening in Nigeria

Sickle cell disease affects millions of Nigerians, and an even larger number carry the sickle cell trait without knowing it. For many families, the first sign of trouble comes only after a child is born with the disease, at which point the conversation shifts from prevention to lifelong management.

This is where genomic screening changes the story. A simple genetic test can tell a couple, before marriage or before pregnancy, whether they both carry the sickle cell trait, and therefore what the odds are of having a child with the disease. Armed with that information, families can make informed choices, and health systems can plan for early intervention rather than late diagnosis.

The challenge in Nigeria has never been a lack of need. It has been a lack of access. Genomic screening infrastructure is concentrated in a handful of urban teaching hospitals, far out of reach for most families, particularly in rural and semi-urban communities. Cost, awareness, and simple physical distance all stand in the way.

This is the gap Centre-GPMI's second pilot program is designed to close. Building on the trust and awareness established through our genomic literacy campaign, we are working toward free, in-house sickle cell screening for one to two thousand individuals, paired with clear referral pathways for anyone who screens positive. It is a modest number in the context of Nigeria's overall burden, but it is a deliberate first step toward a screening model that can eventually scale well beyond Plateau State.